Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MedTech-related health technology assessments from NIHR in December 2021

The National Institute for Health Research (NIHR) funds valuable independent research for health and social care decision-makers in England. Reports from the Health Technology Assessment (HTA) Programme are published in the NIHR HTA Journal and inform NICE guidance.

In December 2021, two MedTech-related assessments were published in the NIHR HTA Journal:

  • Improving continence in children and young people with neurodisability, an assessment based on a systematic review and survey. Treatment approaches may include pharmacotherapy, surgical interventions (e.g., intravesical electrical stimulation, sacral neuromodulation), assistive technologies, and behavioral interventions. Currently, there is uncertainty about which interventions are effective. The study's objective was to summarise the available evidence on and current practice for improving continence in children and young people with neurodisability. It was concluded that there is a lack of good-quality evidence for many of the interventions currently in use and no evidence about the experiences of children and young people with non-spinal-cord-related pathology. There was also no evidence of the cost-effectiveness of any of the interventions;
  • Primary trabeculectomy versus primary glaucoma eye drops for newly diagnosed advanced glaucoma, based on randomized controlled trial (TAGS). The objectives were to compare primary medical management with primary surgical treatment (augmented trabeculectomy) in patients with primary open-angle glaucoma presenting with advanced disease in terms of health-related quality of life, clinical effectiveness, safety, and cost-effectiveness. This trial found no evidence of a difference in visual health-related quality of life between trabeculectomy or glaucoma drops at 24 months;

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).